Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by itntdfon Jun 27, 2024 2:47pm
191 Views
Post# 36109428

It Was Just A Typo

It Was Just A Typoafter twice emailing the "contact us" page at oncolytics, emailing oncy's general counsel, McCarthy Tetrault, and emailing and/or calling both of the investor relations contacts (Jon Patton and Tim McCarthy) I just got off the phone with Tim McCarthy and he said the naming of Bradley G. Thompson as the attorney in fact in the June 3 Registration Statement (the S-8) was a typo.

I said you mean 9 officers and directors signed a document naming Brad as their attorney in fact and not a one of them noticed?  McCarthy said again, it was just a typo.

I ask him if a corrected S-8 would be filed and he said there was no need.

Seems like there is definitely a need since Brad is named an attorney in fact on a legal document filed with the SEC.

The last S-8 I found for oncolytics was filed in September 2015 and it did name both Brad and Kirk as attorneys in fact for that last transaction.

What a completely sloppy filing and equally as sloppy that a correction will not be filed.

B friggin zarre.
<< Previous
Bullboard Posts
Next >>